Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: Compare thrombotic risk in people with congenital hemophilia A (PwcHA) to the general non-hemophilia A (HA) population. Patients & methods: US claims databases were analyzed to identify PwcHA. Incidence rates of myocardial infarction, pulmonary embolism, ischemic stroke, deep vein thrombosis and device-related thrombosis were compared with a matched cohort without HA. Results: Over 3490 PwcHA were identified and 16,380 individuals matched. PwcHA had a similar incidence of myocardial infarction and pulmonary embolism compared with the non-HA population, but a slightly higher incidence of ischemic stroke and deep vein thrombosis. The incidence of device-related thrombosis was significantly higher in PwcHA. Conclusion: This analysis suggests that PwcHA are not protected against thrombosis, and provides context to evaluate thrombotic risk of HA treatments.
Supplementary Material
File (supplementary materials.docx)
- Download
- 54.34 KB
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J. Rare Dis. 7, 24 (2012).
2.
Srivastava A, Santagostino E, Dougall A et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 26(S6), 1–158 (2020).
3.
Kamphuisen PW, ten Cate H. Cardiovascular risk in patients with hemophilia. Blood 123(9), 1297–1301 (2014).
• Summarizes important background context on risk of thrombotic events (TEs), such as myocardial infarction in people with hemophilia, speculating that their hypocoagulable state could offer protection against thrombus formation.
4.
Pocoski J, Ma A, Kessler CM, Boklage S, Humphries TJ. Cardiovascular comorbidities are increased in U.S. patients with haemophilia A: a retrospective database analysis. Haemophilia 20(4), 472–478 (2014).
•• This study of US claims data from 2007 to 2009 quantified cardiovascular comorbidities in people with hemophilia A (PwHA, n = 2506) compared with a matched non-hemophilia A (HA) population (n = 7518) and found that the former had a higher prevalence of ischemic stroke, arterial thrombosis and venous thrombosis.
5.
Tuinenburg A, Rutten A, Kavousi M et al. Coronary artery calcification in hemophilia A: no evidence for a protective effect of factor VIII deficiency on atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 32(3), 799–804 (2012).
•• This population-based imaging study in The Netherlands found no evidence of a protective effect of HA against atherosclerosis.
6.
Sood SL, Cheng D, Ragni M et al. A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Adv. 2(11), 1325–1333 (2018).
7.
Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev. 27(4), 179–184 (2013).
8.
Gomez K, Klamroth R, Mahlangu J, Mancuso ME, Mingot ME, Ozelo MC. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 12(Suppl. 1), S319–S329 (2014).
9.
Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J. Thromb. Haemost. 16(12), 2362–2374 (2018).
10.
Spadarella G, Di Minno A, Milan G et al. Paradigm shift for the treatment of hereditary haemophilia: towards precision medicine. Blood Rev. 39, 100618 (2020).
11.
Callaghan MU, Sidonio R, Pipe SW. Novel therapeutics for hemophilia and other bleeding disorders. Blood 132(1), 23–30 (2018).
12.
Kitazawa T, Esaki K, Tachibana T et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb. Haemost. 117(7), 1348–1357 (2017).
13.
Weyand AC, Pipe SW. New therapies for hemophilia. Blood 133(5), 389–398 (2019).
14.
Ljung R, Fischer K, Carcao M et al. Practical considerations in choosing a factor VIII prophylaxis regimen: role of clinical phenotype and trough levels. Thromb. Haemost. 115(5), 913–920 (2016).
15.
Lambert T, Benson G, Dolan G et al. Practical aspects of extended half-life products for the treatment of haemophilia. Ther. Adv. Hematol. 9(9), 295–308 (2018).
16.
Wolberg AS, Aleman MM, Leiderman K, Machlus KR. Procoagulant activity in hemostasis and thrombosis: virchow's triad revisited. Anesth. Analg. 114(2), 275–285 (2012).
• Considers the pathophysiologic mechanisms underlying TEs, providing important theory behind how a hypercoagulable state and thrombotic tendency could develop if the hemostatic balance is shifted too far with therapeutic approaches to inherited hemorrhagic and thrombotic disorders.
17.
Jenkins PV, Rawley O, Smith OP, O'Donnell JS. Elevated factor VIII levels and risk of venous thrombosis. Br. J. Haematol. 157(6), 653–663 (2012).
18.
Franchini M. Thrombotic complications in patients with hereditary bleeding disorders. Thromb. Haemost. 92(08), 298–304 (2004).
19.
Ruiz-Sáez A. Thrombosis in rare bleeding disorders. Hematology 17(Suppl. 1), S156–S158 (2012).
• Describes the conditions and risk factors associated with thrombosis in PwHA.
20.
Oldenburg J, Mahlangu JN, Kim B et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N. Engl. J. Med. 377(9), 809–818 (2017).
21.
Makris M. Thrombosis in bleeding disorders. In: The ISTH Workshop on Thrombosis and Hemostasis. International Society on Thrombosis and Haemostasis, Bangkok, Thailand (2017).
22.
Biere-Rafi S, Baarslag MA, Peters M et al. Cardiovascular risk assessment in haemophilia patients. Thromb. Haemost. 105(02), 274–278 (2011).
23.
Šrámek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 362(9381), 351–354 (2003).
24.
Faghmous I, Flores C, Sarouei K et al. Estimating the risk of myocardial infarction in persons with hemophilia A using a machine-learning approach with US claims data. 61st ASH (American Society of Hematology) Annual Meeting & Exposition. https://www.cpg-medicaleducation.de/media/faghmous_ash_2019_mi_haemophilia_a_1.pdf
25.
Meyfroidt G, Güiza F, Ramon J, Bruynooghe M. Machine learning techniques to examine large patient databases. Best Pract. Res. Clin. Anaesthesiol. 23(1), 127–143 (2009).
26.
Lyons J, Desai V, Xu Y et al. Development and validation of an algorithm for identifying patients with hemophilia A in an administrative claims database. Value Health 21(9), 1098–1103 (2018).
27.
Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus. 9(2), 120–138 (2011).
• Summarizes risk factors for thrombosis in the general population: hyperlipidemia, smoking, diabetes, hypertension and obesity for arterial TEs; trauma or fractures, surgery, hormonal therapy, pregnancy, hypercoagulability and age for venous TEs.
28.
Ewenstein BM, Valentino LA, Journeycake JM et al. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia 10(5), 629–648 (2004).
29.
Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia 10(2), 134–146 (2004).
•• This systematic review and meta-analysis of complications associated with central venous access devices summarized their risk of thrombosis, due to the combination of the thrombogenic potential of the central venous access device with regular administration of clotting factor concentrates, which predisposes the site around the tip of the catheter to thrombus formation.
30.
Jaffray J, Witmer C, O'Brien SH et al. Peripherally inserted central catheters lead to a high risk of venous thromboembolism in children. Blood 135(3), 220–226 (2020).
31.
Buttigieg J, Asciak R, Azzopardi CM. Pacemaker lead-associated thrombosis in cardiac resynchronisation therapy. BMJ Case Rep. 2015, (2015).
32.
Chang TR, Albright KC, Boehme AK et al. Factor VIII in the setting of acute ischemic stroke among patients with suspected hypercoagulable state. Clin. App. Thromb. Hemost. 20(2), 124–128 (2014).
•• Demonstrates that high factor VIII (FVIII) levels are a risk factor for both ischemic stroke; in some settings, such as surgery, replacement therapies lead to elevated levels of FVIII in PwHA and could therefore increase risk of TEs.
33.
Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N. Engl. J. Med. 343(7), 457–462 (2000).
34.
Hazendonk HCAM, van Moort I, Mathôt RAA et al. Setting the stage for individualized therapy in hemophilia: what role can pharmacokinetics play? Blood Rev. 32(4), 265–271 (2018).
35.
Timmer MA, Pisters MF, de Kleijn P, de Bie RA, Schutgens REG, Veenhof C. Movement behaviour in adults with haemophilia compared to healthy adults. Haemophillia 24(3), 445–451 (2018).
36.
Janczar S, Fogtman A, Koblowska M et al. Novel severe hemophilia A and moyamoya (SHAM) syndrome caused by Xq28 deletions encompassing F8 and BRCC3 genes. Blood 123(25), 4002–4004 (2014).
37.
Miskinyte S, Butler MG, Hervé D et al. Loss of BRCC3 deubiquitinating enzyme leads to abnormal angiogenesis and is associated with syndromic moyamoya. Am. J. Hum. Genet. 88(6), 718–728 (2011).
38.
Roh D, Roth W, Al-Mufti F et al. The utility of factor VIII infusion in a rare case of SHAM Syndrome (P4.343). Neurology 86(Suppl. 16), P4.343 (2016).
39.
Martin K, Key NS. How I treat patients with inherited bleeding disorders who need anticoagulant therapy. Blood 128(2), 178–184 (2016).
40.
Makris M, Iorio A, Lenting PJ. Emicizumab and thrombosis: the story so far. J. Thromb. Haemost. 17(8), 1269–1272 (2019).
41.
Tyree PT, Lind BK, Lafferty WE. Challenges of using medical insurance claims data for utilization analysis. Am. J. Med. Qual. 21(4), 269–275 (2006).
42.
Kurian AK, Cardarelli KM. Racial and ethnic differences in cardiovascular disease risk factors: a systematic review. Ethn. Dis. 17(1), 143–152 (2007).
43.
White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb. Res. 123(Suppl. 4), S11–S17 (2009).
Information & Authors
Information
Published In
Pages: 1323 - 1336
PubMed: 34676773
Copyright
© 2021 F. Hoffmann-La Roche Ltd. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 21 May 2021
Accepted: 30 September 2021
Published online: 22 October 2021
Keywords:
Topics
Authors
Funding Information
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data. (2021) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2021-0120
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Guy Young, Kaan Kavakli, Robert Klamroth, Tadashi Matsushita, Flora Peyvandi, Steven W. Pipe, Savita Rangarajan, Ming-Ching Shen, Alok Srivastava, Jing Sun, Huyen Tran, Chur-Woo You, Bülent Zülfikar, Laurel A. Menapace, Chuanwu Zhang, Yuqian Shen, Marja Puurunen, Marek Demissie, Gili Kenet, Teh-Liane Khoo, Scott Dunkley, Stephanie P'ng, Dominic Pepperell, Stephanie Lam, Elizabeth Steinepreis, Jacques Malherbe, Tulene Kendrick, Marcus Lombard, Huyen Tran, Jessie Zhao, Hannah Stevens, Caroline Dix, James McFadyen, Jean St-Louis, Jeannine Kassis, Georges Rivard, Jing Sun, Xiaofang Li, Huiping Li, Jieyu Ye, Xuan Zhou, Dong Du, Xuefeng Wang, Jing Dai, Quilan Ding, Wenman Wu, Yiyi Lu, Runhui Wu, Guoqing Liu, Wanru Yao, Yan Wang, Yunyun Wei, Weiqun Xu, Yu Du, Liyao Xu, Di Wang, Chan Liao, Hongwei Zhang, Ziqiang Yu, Hong Tian, Haibo Wang, Jie Yin, Tienan Zhu, Huacong Cai, Juan Xiao, Shujie Wang, Shufen Liu, Kaini Shen, Yun Chen, Yali Chang, Tan Sang, Jun Zhao, Yawei Zhou, Liya Zhai, Xiadong Qiu, Yulei He, Hui Li, Yi Xia, Min Zhou, Feng Gao, Shipin Feng, Xiaoli Luo, Dan Li, Zhongguang Cui, Chunzhu Zhao, Hong Xu, Lingjie Sun, Xue Shi, Xiaojing Zeng, Lu Qi, Shuyun Cao, Zeping Zhou, Fuhou Zhang, Lingmei Yin, Hongli Mu, Hui Bi, Zhengchao Li, Yaping Miu, Yaming Xi, Mingfeng Jia, Long Zhao, Xielan Zhao, Yaochun Li, Jie Peng, Chia-Yau Chang, Yen-Lin Liu, Ming-Ching Shen, Cheng-Wei Huang, Shih-Chung Wang, Hsuan-Yu Lin, Ching-Yeh Lin, Sheng-Chieh Chou, Ming-Kai Chuang, Szu-Chun Hsu, Jiaan-Der Wang, Ming-Yang Shih, Liang-Tsai Hsiao, Giun-Yi Hung, Hsiu-Ju Yen, Po-Shen Ko, Hung Chang, Shih-Hsaing Chen, Te-Fu Weng, Yu-Hua Chao, Sherig-Wei Zeng, Peter Kampmann, Eva Funding, Yesim Dargaud, Claude Negrier, Stéphanie Desag, Laurent Frenzel, Guillemette Fouquet, Cécile Bally, Robert Klamroth, Ana-Marija Orlovic, Christian Pfrepper, Michael Metze, Rima Chakaroun, Maria Weise, László Nemes, Agnes Ronatas, Cecil Ross, Seetharam Anandram, Vandana Bharadwaj, Sonali Salvi, Sunil Lohande, Alok Srivastava, Aby Abraham, Fouzia Aboobacker, Shailendra Verma, Gaurav Datta, Savita Rangarajan, Shweta Bansal, Shashikant Apte, Kannan Subramanian, Beatrice Nolan, Saad Ahmed, Niamh O’Connell, James O’Donnell, Kevin Ryan, Michelle Lavin, Gili Kenet, Omri Cohen, Mudi Misgav, Assaf Barg, Sarina Levy Mendelovich, Flora Peyvandi, Roberta Gualtierotti, Ezio Zanon, Luca Spiezia, Chiara Simion, Tadashi Matsushita, Shuichi Okamoto, Nobuaki Suzuki, Takeshi Kanematsu, Naruko Suzuki, Yuka Kawaguchi, Satoshi Higasa, Tazuko Tokugawa, Akihiro Sawada, Rie Shirayama, Masaru Kawamura, Hiroshi Asai, Koichi Oshida, Tetsuji Sato, Takuma Ito, Katsuyoshi Koh, Yoshitaka Mizushima, Takahiro Ishikawa, Hirohito Kubota, Ryota Kaneko, Tomoya Irikura, Mamoru Honda, Katsuaki Taira, Yuki Arakawa, Makiko Mori, Kohei Fukoka, Koichi Oshima, Yuichi Mitani, Yoshiaki Ogawa, Kiyoshi Ando, Rikio Suzuki, Ryujiro Hara, Yasuyuki Aoyama, Masako Toyosaki, Daisuke Ogiya, Shinichiro Machida, Hiroshi Kawada, Yukari Shirasugi, Makoto Onizuka, Ken Omachi, Kagehiro Amano, Tomoko Yamaguchi, Ei Kinai, Takeshi Hagiwara, Mihoko Yotsumoto, Ryoko Sekiya, Masato Bingo, Yushi Chikasawa, Akito Ichiki, Yoshiko Kamikubo, Ryui Miyashita, Takashi Muramatsu, Ho-Jin Shin, DoYoung Kim, Chur-Woo You, Ju Young Kim, Seung Min Hahn, Chuhl Joo Lyu, Jung Woo Han, Young Shil Park, Ja Hyang Cho, Azizan Shariq, Soo Min Lim, Lily Wong, Heng Chang Choo, Gilbert Wilfred, Mohd Tarmizi Ahmad Zakhi, Yin Man Lim, Khaiteri Raghunathan, Jameela Sathar, Syazarin Fidhora Nasution, Yee Yee Yap, Veena Selvaratnam, Daniel Malan, Zelda Erika Punt, Ali Bulent Antmen, Ilgen Sasmaz, Utku Aygunes, Kaan Kavakli, Nihal Karadas, Deniz Karapinar, Alphan Kupesiz, Mine Erkan, Kupesiz Funda Tayfun, Elif Guler, Bulent Zulfikar, Basak Koc, Vahap Okan, Sahin Handan Haydaroglu, Canan Albayrak, Ibrahim Kartal, Ebru Yilmaz, Musa Karakukcu, Ekrem Unal, Alper Ozcan, Fahri Sahin, Betul Tuzun, Guray Saydam, Ievgenii Averianov, Oksana Kovtunenko, Oleksandra Stasyshyn, Maksym Semerak, Orest Tushnytskyy, Kateryna Vilchevska, Iryna Bakhchyvandzhy, Nataliya Romanyuk, Stanislav Nikulin, Alina Kobets, Jayanthi Alamelu MRCPCH, Samah Babiker, Catherine Bagot, James Tyan Rodgers, Lisa Boggio, Mindy Simpson, Erin Cockrell, Candance DeBerry, Dana Obzut, John Fargo, Jeffrey Hord, Stephanie Savelli, Joseph Lasky, Jennifer Buitrago, Waseem Alhushki, Cynthia Gauger, Darren Klawinski, Eric Sandler, Scott Bradfield, Paul Pitel, Michael Joyce, Howard Katzenstein, Manisha Bansal, Allison Bechtel, Christine Knoll, Esteban Gomez, Shanna White, Sanjay Shah, Joanna Gendreau, Lori Wagner, Maa-Ohui Quarmyne, Larissa Bornikova, Colleen Cleary CNP, Pamela G. Hodges, Alexandra Mossali, Rachel Rosovsky, Victoria Turbini, Valerie Wood, Hanny Al-Samkari, Steven Pipe, Angela Weyand, Jordan Shavit, Amit Soni, Diane Nugent, Nina Hwang, Vanessa Salinas, Guy Young, Tom Hofstra, Jennifer Donkin, Jacquelyn Keegan, Zaheer Sibgha, Wendy Leung, Julie Jaffray, Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study, Blood, 10.1182/blood.2024027008, 145, 25, (2966-2977), (2025).
- Massimo Franchini, Daniele Focosi, Pier Mannuccio Mannucci, Thrombotic Complications in Hemophilia: An Intricate Conundrum, Seminars in Thrombosis and Hemostasis, 10.1055/a-2603-0344, 52, 02, (164-173), (2025).
- Hideo Wada, Katsuya Shiraki, Takeshi Matsumoto, Hideto Shimpo, Yumi Sakano, Hiroko Nishii, Shigehisa Tamaki, Kei Suzuki, Isao Tawara, Yoshiki Yamashita, Motomu Shimaoka, Evaluating Factor VIII Concentrates Using Clot Waveform Analysis, Journal of Clinical Medicine, 10.3390/jcm13133857, 13, 13, (3857), (2024).
- Takeshi Matsumoto, Hideo Wada, Katsuya Shiraki, Kei Suzuki, Yoshiki Yamashita, Isao Tawara, Hideto Shimpo, Motomu Shimaoka, The Evaluation of Clot Waveform Analyses for Assessing Hypercoagulability in Patients Treated with Factor VIII Concentrate, Journal of Clinical Medicine, 10.3390/jcm12196320, 12, 19, (6320), (2023).
- Pier Mannuccio Mannucci, Pasquale Agosti, Maddalena Lettino, Guidance for the antithrombotic management of persons with haemophilia and cardiovascular disease, Haemophilia, 10.1111/hae.14874, 29, 6, (1390-1393), (2023).
- Armando Tripodi, Pier Mannuccio Mannucci, Flora Peyvandi, Hemophilia patients: are they naturally anticoagulated?, Internal and Emergency Medicine, 10.1007/s11739-023-03331-7, 18, 5, (1251-1254), (2023).
- Christina Schnohr, Ola Ekholm, Lone Hvitfeldt Poulsen, Lars Lehrmann, Terkel Andersen, Eva Funding, Karen Binger Holm, Jakob Bue Bjorner, Health and quality of life of patients with haemophilia: A national study of 124 Danish men, Haemophilia, 10.1111/hae.14751, 29, 2, (538-544), (2023).
- Amy D. Shapiro, Brandon M. Hardesty, Flora Peyvandi, Alfonso Iorio, Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review, Research and Practice in Thrombosis and Haemostasis, 10.1016/j.rpth.2022.100007, 7, 1, (100007), (2023).